Recommendations on the use of 5-amino-levulinic acid in surgery of malignant gliomas. Consensus document;Recomendaciones sobre el uso de ácido 5-aminolevulínico en la cirugía de los gliomas malignos. Documento de consenso

Neurocirugia

Volumn 24, Issue 4, 2013, Pages 163-169

  Gil Salú, José Luis ^a   Arraez, Miguel Ángel ^b   Barcia, Juan Antonio ^c   Piquer, José ^d   De Lope, Ángel Rodríguez ^e   Martínez, Gloria Villalba ^f  

^a HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

^b HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d HOSPITAL DE LA RIBERA   (Spain)

^e HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^f HOSPITAL DEL MAR   (Spain)

Author keywords

5 amino levulinic acid; High grade gliomas; Surgery

Indexed keywords

AMINOLEVULINIC ACID;

ARTICLE; CANCER GRADING; CANCER SURGERY; COMORBIDITY; CONSULTATION; DRUG USE; FLUORESCENCE; GLIOBLASTOMA; HUMAN;

EID: 84888354598     PISSN: 11301473     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neucir.2013.01.004     Document Type: Article

References (27)

1. NCCN Clinical Practice Guidelines in Oncology. Central Nervous System Cancers. National Comprehensive Cancer Network, 2012.
2. Brem SS, Bierman PJ, Brem H, Butowski N, Chamberlain MC, Chiocca EA, et al. Central nervous system cancers. J Natl Compr Canc Netw. 2011; 9: 352-400.
3. Central Brain Tumor Registry of the United States. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2004-2006 [actualización 2010; consultado 29 Nov 2010]. Disponible en: http://www.cbtrus.ort/reports/reports.html
4. Tonn JC, Stummer W. Fluorescence-guided resection of malignant gliomas using 5-aminolevulinic acid: practical use, risks, and pitfalls. Clin Neurosurg. 2008; 55: 20-6.
5. Salcman M. Surgical resection of malignant brain tumors: who benefits? Oncology (Williston Park, N Y). 1988; 2: 47-56, 59-60, 63.
6. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352: 987-96.
7. Stupp R, Roila F. Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008; 19 Suppl 2:ii83-5.
8. Vuorinen V, Hinkka S, Farkkila M, Jaaskelainen J. Debulking or biopsy of malignant glioma in elderly people - a randomised study. Acta Neurochir (Wien). 2003; 145: 5-10.
9. Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg. 2011; 115: 3-8.
10. Stummer W, Stocker S, Wagner S, Stepp H, Fritsch C, Goetz C, et al. Intraoperative detection of malignant gliomas by 5-aminolevulinic acid-induced porphyrin fluorescence. Neurosurgery. 1998; 42: 518-25, discussion 25-26.
11. Wisoff JH, Boyett JM, Berger MS, Brant C, Li H, Yates AJ, et al. Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children's Cancer Group trial no. CCG-945. J Neurosurg. 1998; 89: 52-9.
12. Pesudo Martinez JV, Belloch Ugarte V, González-Darder JM, Vera Roman J, Feliu Tatay R, Gil Salú JL. Valoración del grado de resección de los gliomas supratentoriales de alto grado con resonancia magnética postoperatoria precoz. Neurocirugia (Astur). 2001; 12: 43-50.
13. Diez Valle R, Tejada Solis S, Idoate Gastearena MA, Garcia de Eulate R, Dominguez Echavarri P, Aristu Mendiroz J. Surgery guided by 5-aminolevulinic fluorescence in glioblastoma: volumetric analysis of extent of resection in single-center experience. J Neurooncol. 2011; 102: 105-13.
14. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al., Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group. J Clin Oncol. 2010; 28: 1963-72.
15. Eljamel MS. Fluorescence image-guided surgery of brain tumors: Explained step-by-step. Photodiagnosis Photodyn Ther. 2008; 5: 260-3.
16. UNICEF. Visualisation in participatory programmes. A manual for facilitators and trainers involved in participatory group events. Bangladesh; 1993 [consultado 10 Oct 2011]. Disponible en: http://www.jhuccp.org/sites/all/ files/VIPPmanual.pdf
17. SIGN. Scottish Intercollegiate Guidelines Network. Edinburgh 2008 [consultado 10 Oct 2011]. Disponible en: http://http://www.sign.ac.uk/pdf/ sign50.pdf
18. Oxford Centre for Evidence-based Medicine [sede Web]. Oxford. Levels of Evidence and Grades of Recommendation [consultado 15 May 2007]. Disponible en: http://www.cebm. net/index.aspx?o=1047
19. EMA. European Medicines Agency. London 2007 [consultado 10 Oct 2011]. Disponible en: http://www.ema.europa.eu/docs/es ES/document library/EPAR - Summary for the public/human/000744/WC500021786.pdf
20. EMA. European Medicines Agency. London 2007 [consultado 10 Oct 2011]. Disponible en: http://www.ema.europa.eu/docs/es ES/document library/EPAR - Product Information/human/000744/WC500021790.pdf
21. Rovira V.P.J., Llacer J.L., Riesgo P. Telescopia fluorescente guiada mediante neuronavegación en la cirugía del glioblastoma multiforme. Comunicación oral presentada al XVI Congreso Nacional de la SENEC. Madrid, 2011.
22. Eljamel MS. Which intracranial lesions would be suitable for 5-aminolevulenic acid-induced fluorescence-guided identification, localization, or resection? A prospective study of 114 consecutive intracranial lesions. Clin Neurosurg. 2009; 56: 93-7.
23. Stummer W, Tonn JC, Mehdorn HM, Nestler U, Franz K, Goetz C, et al. Counterbalancing risks and gains from extended resections in malignant glioma surgery: A supplemental analysis from the randomized 5-aminolevulinic acid glioma resection study. Clinical article. J Neurosurg. 2011; 114: 613-23.
24. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase iii trial. Lancet Oncol. 2006; 7: 392-401.
25. Gil-Salu JL, Roman P, Benitez E, Maestro E, Perez-Requena J, Lopez-Escobar M. Survival analysis following the addition of temozolomide to surgery and radiotherapy in patients with glioblastoma multiforme. Neurocirugia (Astur). 2004; 15: 144-50.
26. Slof J, Diez-Valle R, Galván J. Libro de resúmenes del XVI Congreso Nacional de la SENEC, 24-27 de mayo de 2011, Madrid. Determinación del coste por resección completa adicional conseguida con cirugía del glioma maligno guiada por fluorescencia con 5-aminolevulínico (5-ALA) frente a luz blanca (póster).
27. Slof J, Diez-Valle R, Galván J. Libro de resúmenes de las XXXI Jornadas de Economía de la Salud, 3-6 de mayo de 2011, Palma de Mallorca. Análisis coste-efectividad de la cirugía del glioma maligno guiada por fluorescencia con 5-aminolevulínico (5-ALA) (póster).